Publication|Articles|October 6, 2025
Supplements and Featured Publications
- The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Remove Black Box Warnings From HRT, Debate Ensues
2
POLY-HF: Polypill Boosts Heart Function, Adherence in Heart Failure
3
Risk-Based Contracts May Not Cut Low-Value Care in Medicare Advantage
4
Tirzepatide’s Dual Approach Better for MACE, HF: Stephen Nicholls, MBBS
5











































